Evidence map›Paper›PMID 37045567›Full record

ArticleBMJ open2023

Cohort profile: SUPER-Finland - the Finnish study for hereditary mechanisms of psychotic disorders.

Markku Lähteenvuo, Ari Ahola-Olli, Kimmo Suokas, Minna Holm, Zuzanna Misiewicz, Tuomas Jukuri, Teemu Männynsalo, Asko Wegelius, Willehard Haaki, Risto Kajanne and 18 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Suicidal acts and thoughts among persons with psychotic disorders in the Finnish SUPER study.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 9 institutions in 4 countries.

Markku LähteenvuoDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland markku.lahteenvuo@niuva.fi.ORCID 0000-0002-7244-145X
Ari Ahola-OlliInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4451-3487
Kimmo SuokasFaculty of Social Sciences, Tampere University, Tampere, Finland.ORCID 0000-0001-6296-6343
Minna HolmFinnish Institute for Health and Welfare, Helsinki, Finland.
Zuzanna MisiewiczInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Tuomas JukuriDepartment of Psychiatry, Oulu University Hospital, Oulu, Finland.
Teemu MännynsaloPsychiatric and Substance Abuse Services, City of Helsinki, Helsinki, Finland.
Asko WegeliusDepartment of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.
Willehard HaakiDepartment of Psychiatry, University of Turku, Turku, Finland.
Risto KajanneInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Aija KyttäläFinnish Institute for Health and Welfare, Helsinki, Finland.
Annamari Tuulio-HenrikssonDepartment of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.
Kaisla LahdensuoInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Katja HäkkinenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Jarmo HietalaDepartment of Psychiatry, University of Turku, Turku, Finland.
Tiina PaunioFinnish Institute for Health and Welfare, Helsinki, Finland.
Jussi Niemi-PynttäriPsychiatric and Substance Abuse Services, City of Helsinki, Helsinki, Finland.
Tuula KieseppäDepartment of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.
Juha VeijolaResearch Unit of Clinical Neuroscience, Department of Psychiatry, University of Oulu, Oulu, Finland.
Jouko LönnqvistFinnish Institute for Health and Welfare, Helsinki, Finland.
Erkki IsometsäDepartment of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.
Olli KampmanFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Jari TiihonenDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
Steven HymanStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Benjamin NealeStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Mark DalyInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Jaana SuvisaariFinnish Institute for Health and Welfare, Helsinki, Finland.
Aarno PalotieInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
University of Helsinki · FIBroad Institute · USHelsinki University Hospital · FIFinnish Institute for Health and Welfare · FIUniversity of Turku · FIOulu University Hospital · FISubstance Abuse and Mental Health Services Administration · USUniversity of Eastern Finland · FITampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSUPER-Finland is a large Finnish collection of psychosis cases. This cohort also represents the Finnish contribution to the Stanley Global Neuropsychiatric Genetics Initiative, which seeks to diversify genetic sample collection to include Asian, Latin American and African populations in addition to known population isolates, such as Finland.

participants10 474 individuals aged 18 years or older were recruited throughout the country. The subjects have been genotyped with a genome-wide genotyping chip and exome sequenced. A subset of 897 individuals selected from known population sub-isolates were selected for whole-genome sequencing. Recruitment was done between November 2015 and December 2018. FINDINGS TO DATE: 5757 (55.2%) had a diagnosis of schizophrenia, 944 (9.1%) schizoaffective disorder, 1612 (15.5%) type I or type II bipolar disorder, 532 (5.1 %) psychotic depression, 1047 (10.0%) other psychosis and for 530 (5.1%) self-reported psychosis at recruitment could not be confirmed from register data. Mean duration of schizophrenia was 22.0 years at the time of the recruitment. By the end of the year 2018, 204 of the recruited individuals had died. The most common cause of death was cardiovascular disease (n=61) followed by neoplasms (n=40). Ten subjects had psychiatric morbidity as the primary cause of death. FUTURE PLANS: Compare the effects of common variants, rare variants and copy number variations (CNVs) on severity of psychotic illness. In addition, we aim to track longitudinal course of illness based on nation-wide register data to estimate how phenotypic and genetic differences alter it.

Indexed as

Bipolar DisorderPsychotic DisordersSchizophreniaDNA Copy Number VariationsFinlandHumansDepression & mood disordersPSYCHIATRYSchizophrenia & psychotic disorders

Identifiers

PMID37045567
PMCPMC10106053
OpenAlexW4365141198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.